ROCKVILLE, Md., Sept. 14 /PRNewswire-FirstCall/ -- Novavax Inc. today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, will present a corporate overview and highlight recent developments at the 2007 UBS Global Life Sciences Conference on Monday, September 24, 2007 at 9:30 a.m. Eastern Time at the Grand Hyatt Hotel in New York City.
A link to Dr. Singhvi's live web cast of Novavax's presentation will be available through the company's website http://www.novavax.com and will be archived on the Novavax website for 30 days.
ABOUT NOVAVAX
Novavax Inc. is a clinical-stage vaccine company committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
Novavax, Inc.CONTACT: Tricia J. Richardson, Investor Relations Manager of Novavax,Inc., +1-240-268-2031
Web site: http://www.novavax.com/
